CHORD1: Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Study Details
Study Description
Brief Summary
This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question.
This study will recruit 125 participants with Type 1 Diabetes (T1D) to:
-
Analyze the effect of reducing the cholesterol levels in the blood on platelet function. (Platelets are small cells in the blood which help form blood clots to slow or stop bleeding and to help wounds heal
-
Analyze the effect of reducing the cholesterol levels in the blood on While Blood Cell (WBC) gene expression, (White Blood Cells are part of the body's immune system which help the body fight infection and other diseases) and
-
Analyze the effect of reducing the cholesterol levels in the blood on vascular or blood vessel function.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Participants will receive weekly injections of PCSK9i (evolocumab) plus daily, oral pills of atorvastatin or ezetimibe for 1 month.
Participants will undergo blood draw, and optional vascular studies that include:
-
Glycocalyx testing (A non-invasive test where a video microscope camera is placed under the tongue to capture images of the movement of red blood cells as they travel through the micro-blood vessels)
-
PET/CT for vascular imaging - to assess any inflammation of blood vessels and to evaluate increased metabolism in related tissues, and
-
Endothelial cell collection before cholesterol reduction and 1-month after cholesterol reduction to measure any genetic changes in in the endothelial cells before and after collection
Glycemic Variability (GV), the amount one's blood sugar changes throughout the day, will be analyzed from continuous glucose monitoring (CGM) data.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 4-Week LDL-Cholesterol (LDL-C)-Reduction Treatment Treatment consists of: Evolocumab (140 mg; 2 injections, one administered at baseline visit and another self-administered 2 weeks later), and; Atorvastatin (up to 80mg dose; 1 tab per day for 30 days, starting at baseline visit post-assessment). Participants with statin intolerance will be provided with a 1-month supply of ezetimibe 10 mg to replace Evolocumab and Atorvastatin. Additional procedures: Blood draws. Optional procedures: Glycocalyx testing, PET/CT, or Endothelial Cell Collection. |
Drug: Evolocumab Cartridge
Injectable PCSK9 inhibitor.
Other Names:
Drug: Atorvastatin Calcium Tablets
HMG-CoA reductase inhibitor for oral use.
Other Names:
Drug: Ezetimibe Tablets
Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.
Other Names:
Drug: 18F-FDG
Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.
Device: Angiocatheter 20IV
Optional procedure (endothelial cell harvesting). An angiocatheter ≤ 21 gauge will be inserted into a peripheral vein on the upper extremity using aseptic technique. A 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be then advanced into the angiocatheter, to a distance of 4cm beyond the end of the angiocatheter.
Other Names:
Device: J-Wire
Optional procedure (endothelial cell harvesting). Either a 0.021in. diameter J-shaped wire (Daig, Minnetonka, MN) or a 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be used.
Device: GlycoCheck Glycocalyx Measurement Software
Optional procedure (assessment of vascular function). Video microscope developed by GlycoCheck.
|
Outcome Measures
Primary Outcome Measures
- Change in Monocyte Platelet Aggregation (MPA) from Baseline [Baseline, Week 4]
Measurement of platelet activity. Assessed via patient blood sample.
- Change in Light Transmission Aggregation (LTA) from Baseline [Baseline, Week 4]
Measurement of platelet activity. Assessed via patient blood sample.
Secondary Outcome Measures
- Percent Change in Natural Killer (NK) Cell Population from Baseline [Baseline, Week 4]
Assessed via patient blood sample.
- Percent Change in Dendritic Cell Population from Baseline [Baseline, Week 4]
Assessed via patient blood sample.
- Percent Change in CD8 Cell Population from Baseline [Baseline, Week 4]
Assessed via patient blood sample.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants with previous diagnosis of T1D (as defined by American Diabetes Association or judgment of physician for at least 1 year)
-
American Diabetes Association Criteria for diagnosis of diabetes (Must meet at least 1 of the following criteria):
-
- FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 hours, OR;
-
- 2-h PG ≥200 mg/dL (11.1 mmol/L) during OGTT. The test should be performed using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water, OR;
-
- A1C ≥6.5% (48 mmol/mol), OR;
-
- In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L), AND;
-
History of T1D (due to autoimmune β-cell destruction, usually leading to absolute insulin deficiency, including latent autoimmune diabetes of adulthood). Autoimmune markers include islet cell autoantibodies and autoantibodies to GAD (glutamic acid decarboxylase, GAD65), insulin, the tyrosine phosphatases islet antigen 2 (IA-2) and IA-2β, and zinc transporter 8, OR;
-
Diagnosis of T1D and confirmed by review of records by 2 separate clinical members of the study team
-
Age ≥ 18 & < 90
-
LDL-C >100mg/dl
-
Able and willing to provide written informed consent for the study
Exclusion Criteria:
-
Established cardiovascular disease on antithrombotic therapy
-
Triglycerides >400mg/dl
-
Use of a PCSK9 inhibitor
-
Recent infection in the past 30 days
-
Any hospitalization in the past 30 days
-
Use of immunosuppressive therapy
-
Use of any antithrombotic therapy
-
Use of aspirin
-
Use of NSAID within the past 72 hours
-
Pregnancy
-
Anemia (hemoglobin < 9 g/dl) or thrombocytopenia (platelet count <75), or thrombocytosis (platelet count >600)
-
A history of hemorrhagic diathesis
-
Chronic kidney disease (CrCl < 30ml/min)
-
T2D, monogenic diabetes syndromes, or diabetes in the context of disease of the exocrine pancreas (such as pancreatitis, trauma or pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | New York VA Hospital | New York | New York | United States | 10010 |
| 2 | NYC Health + Hospitals/Bellevue | New York | New York | United States | 10016 |
| 3 | NYU Langone Health | New York | New York | United States | 10016 |
Sponsors and Collaborators
- NYU Langone Health
- National Heart, Lung, and Blood Institute (NHLBI)
Investigators
- Principal Investigator: Ira Goldberg, MD, NYU Langone Health
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 22-01095